Opthea Q&A Sep 2024 Update, page-28

Not 100% sure what you're asking, but in June-Aug 2026, we would expect the long-term safety follow-up. The only thing that's clear at this point is the scheduled safety follow-up at week 100. Or are you thinking there will be other possible events in Aug 2026, after the OPTOB options expire?

The one thing Opthea gets three gold stars for is spending investor money. In their communications, they stated that the last capital raise was to fund the company until the Phase 3 readout. This implies to me that if the Phase 3 trial is successful, they’ll need even more funding afterward. However, by that point, current shareholders could be seeing big green gains—or big red losses if the Phase 3 trial fails.